---
schema_version: "secwatch.filing_event.v1"
accession: "0001567892-24-000015"
form_type: "8-K"
ticker: null
cik: "0001567892"
company_name: "Keenova Therapeutics plc"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:55:20.376552+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mallinckrodt Q1 net sales up 10.2% to $467.8M; net loss improves 73.8%

## Summary
- Net sales of $467.8M, up 10.2% YoY on a reported and constant currency basis.
- Net loss of $65.4M, a 73.8% improvement from $249.3M in prior year quarter.
- Adjusted EBITDA $144.9M, up 17.3% YoY from $123.5M.
- Acthar Gel net sales $102.8M (+25.4%), Terlivaz $6.0M; Specialty Generics +22.0%.
- Full year guidance reaffirmed; SelfJect launch expected in Q3 2024.

## SEC filing metadata
- accession: 0001567892-24-000015
- form_type: 8-K
- cik: 0001567892
- company_name: Keenova Therapeutics plc
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567892/000156789224000015/0001567892-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567892/000156789224000015/mnk-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567892-24-000015
- JSON: https://secwatch.observer/filing/0001567892-24-000015.json
- Plain text: https://secwatch.observer/filing/0001567892-24-000015.txt

## Key facts
- Earnings Releases
  Keenova Therapeutics plc reported the first quarter ended March 29, 2024 results: revenue $467.8 million, net income net loss of $65.4 million. Guidance reaffirmed.
  - Period: the first quarter ended March 29, 2024
  - Revenue: $467.8 million
  - Net income: net loss of $65.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: in such a filing. --- EX-99.1 (EX-99.1) --- Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance Achieves First Quarter Net Sales of $467.8 Million, Reflecting 10.2% Year-Over-Year Growth on a Reported and Constant Currency Basis Reports Net Loss of $65.4 Million , Reflecting a 73.8% Year-Over-Year Improvement; Delivers
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567892/000156789224000015/0001567892-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.